liothyronine modified release (T3-modified release)
/ T3 Therap, Kyowa Kirin
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 10, 2022
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
(clinicaltrials.gov)
- P2; N=62; Active, not recruiting; Sponsor: Pediatric Brain Tumor Consortium; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed • Brain Cancer • Ependymoma • Medulloblastoma • Oncology • Pediatrics • Solid Tumor • CD276 • MRI
1 to 1
Of
1
Go to page
1